Journal Article

II.4 Monitoring of treatment

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 17, issue suppl_7, pages 24-25
Published in print July 2002 | ISSN: 0931-0509
Published online July 2002 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/17.suppl_7.24-a
II.4 Monitoring of treatment

Show Summary Details

Preview

Guideline II.4.1

A. Indices used to quantify the efficiency of HD depend upon the blood urea concentration in pre‐ and post‐HD blood samples. Therefore, it is crucial that these samples be taken carefully with a standard method.

(Evidence level: A)

Guideline II.4.2

A. The delivered dose of HD should be checked at least monthly.

(Evidence level: B)

B. Renal function may only be included in the assessment if it is measured monthly at the same time as the delivered dose of HD. Because renal function may change over time, historic renal function data may not be used.

Guideline II.4.3

A. If a patient fails to receive the adequate HD dose, or if a significant difference between the prescribed and the delivered dose is observed, a search for the cause of the problem must be undertaken.

(Evidence level: B)

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.